Skip to content

A using test for four continuous weeks of SC1722 against babies

A using test for four continuous weeks of SC1722 against babies - A using test for four continuous weeks of SC1722 against babies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032333
Enrollment
60
Registered
2019-05-10
Start date
2018-05-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Inspection before test start - Use the test sample on the whole body for two weeks - Inspection such as observation and measurement at two weeks after test start - Use the test sample on the whole bo

Sponsors

Inforward, inc EBISU skin research center
Lead Sponsor
Medimate Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Those who satisfy all of the following conditions 1)Healthy babies (male and female) aged 28 days-old to 11 months-old. 2)Subjects who have their protector (parents or guardians) that are able to show their willingness of participating to the test, and that are able to obtain written consent to participate in the test after understanding explanation of test. 3)Subjects and their protectors(parents or guardians) who are able to come to the institution for all inspections.

Exclusion criteria

Exclusion criteria: 1)Premature babies. 2)Subjects with birth weight >2,500g. 3)Subjects who have severe eczema infantile. 4)Subjects who have skin symptom such as atopic dermatitis. 5)Subjects who have trauma on the part that uses the test sample. 6)Subjects who have possibility to take a lot of sunlight. 7)Subjects who are participating in clinical tests and use tests that apply cosmetic, quasi-drugs and others. 8)Subjects who have allergic symptoms against external medicine, cosmetic, quasi-drugs and others in the past. 9)Subjects who have previous and/or current medical history of serious disease in liver, kidney, myocardial infarction. 10)Subject who are going to hospital and being accepted medical treatment due to disease. 11)Subjects who have their family that are working for cosmetic companies and pharmaceutical companies. 12)Others who have been determined ineligible by investigator.

Design outcomes

Primary

MeasureTime frame
Doctor's findings such as dryness or scales, erythema, papules, scratch marks on the whole body prior to starting test and at four weeks after test start.

Secondary

MeasureTime frame
*Doctor's findings such as dryness or scales, erythema, papules, scratch marks on the whole body prior to starting test and at two weeks after test start. *Measuring stratum corneum water content of skin, transepidermal water transpiration amount of skin prior to starting test and at two and four weeks after test start.

Countries

Japan

Contacts

Public ContactKanako Sakurai

Inforward, inc EBISU skin research center

sakurai@inforward.co.jp03-5793-8712

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026